ZVRA vs RGNX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZVRA Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zevra Therapeutics, Inc. Common Stock (ZVRA) driven by superior Valuation, Growth & Margin, Momentum & Technical while RGNX counters with relative strength in Options & Structure. Fundamentally, ZVRA trades at 9.3x Forward P/E with 31.5% operating margin (+44.9% YoY revenue) versus RGNX at N/M Forward P/E and -120.4% operating margin (-69.2% YoY). In options structure, ZVRA sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro) against RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ZVRA Revenue | RGNX Revenue | ZVRA Op. Margin | RGNX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $220M | N/A | 40.3% | RGNX |
| FY2019 | $10M | $40M | -158.4% | -422.9% | ZVRA |
| FY2020 | $10M | $150M | -42.2% | -77.1% | ZVRA |
| FY2021 | $30M | $470M | 27.0% | 34.0% | RGNX |
| FY2022 | $10M | $110M | -418.9% | -233.2% | RGNX |
| FY2023 | $30M | $90M | -180.6% | -297.1% | ZVRA |
| FY2024 | $20M | $80M | -368.5% | -280.0% | RGNX |
| FY2025 | $110M | $170M | -59.1% | -94.6% | ZVRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZVRA | RGNX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $664.1M | $500.9M | Larger Scale | ZVRA |
| Trailing P/E Ratio Valuation | 9.7x | N/M | Lower Multiple | ZVRA |
| Forward P/E Ratio Valuation | 9.3x | N/M | Lower Multiple | ZVRA |
| Revenue Growth (YoY) Growth | +44.9% | -69.2% | Higher Growth | ZVRA |
| Operating Margin (TTM) Profitability | 31.5% | -120.4% | Higher Margin | ZVRA |
| Net Profit Margin Profitability | 52.8% | -113.9% | Higher Margin | ZVRA |
| Return on Equity (ROE) Capital Efficiency | 41.9% | -113.2% | Higher ROE | ZVRA |
| 52-Week Range Position Momentum | 17% ($8โ$15) | 19% ($5โ$16) | Stronger Trend | RGNX |
| Beta / 30D Volatility Risk Regime | 1.18ฮฒ ยท 95% Vol | 1.82ฮฒ ยท 76% Vol | Lower Realized Risk | RGNX |
| Unified Institutional Score Composite Signal | 49.4 / 100 (HOLD) | 45.3 / 100 (HOLD) | Higher Composite | ZVRA |